종설

遲發性 内淋巴水腫

李相哲 1
Sang Cheol Lee 1
Author Information & Copyright ▼
1仁濟大學校 釜山白病院 耳鼻咽喉科學教室
1Department of Otolaryngology, Pusan Paik Hospital, Inje University

© Copyright 1990 The Busan, Ulsan, Gyeoungnam Branch of Korean Society of Otolaryngology-Head and Neck Surgery. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: May 31, 2020

ABSTRACT

Delayed endolymphatic hydrops(DEH), a clinical entity which was described as a syndrome with the characteristic clinical findings such as rotatory vertigo or fluctuating hearing loss on the normal ear appearing a few years after unilateral severe sensori-neural hearing loss or total deafness.

DEH can be differentiated from Meniere’s disease, and was first reported simutaneously by Nadol et al and Wolfson et al in 1975, and was specified by Schuknecht in 1978.

Schuknecht, in 1985, classified DEH into 3 types ; 1) ipsilateral : rotatory vertigo only, 2) contralateral: rotatory vertigo with fluctuating hearing loss on the normal side, and 3) bilateral.

In many cases the hearing loss was caused by juvenile unilateral total deafness of unknown causes, viral diseases such as mumps, other postinflammatory or posttraumatically.

There is no tendency of rule in latency between hearing loss and vertigo or fluctuating hearing loss on opposite ear, and it is more than 10 years in many cases.

Diagnosis is made from history, clinical findings, audiologic and equilibrium function test.

Treatment is similiar to that of Meniere’s disease with conservative (vasodilators, autonomic nerve controlling drugs, steroid, antivertiginous drugs, low salt diet, etc) and surgical method (endolymphatic sac surgery or labyrinthine destruction) in case of no effect by conservative. But, in general, the result of treatment is poorer than in Meniere’s disease.



투고규정 개정 안내

임상이비인후과 투고규정이 2027년 1월 1일부터 개정 시행됩니다.
논문 투고 전 주요 변경사항과 개정된 원고 양식을 확인해 주시기 바랍니다.

주요 변경사항
- 생성형 AI 사용 기준 신설
- 성별·젠더 관련 작성 기준 추가
- 한글 중심단어 작성 기준 추가
- 원고 양식 업데이트

투고규정 전문 보기

임상이비인후과 학술지에 많은 관심과 논문 투고를 부탁드립니다.
감사합니다.


I don't want to open this window for a day.